澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

CSL LIMITED

167.100

-2.400-1.42%

成交量：80.66萬

成交額：1.35億

市值：800.26億

市盈率：-22.40

高：169.360

開：167.000

低：165.790

收：169.500

52周最高：216.751

52周最低：88.837

股本：4.79億

流通股本：4.79億

量比：0.79

換手率：0.17%

股息：4.07

股息率：2.44%

每股收益(TTM):-7.460

每股收益(LYR):-7.460

淨資產收益率：-15.83%

總資產收益率：7.26%

市淨率：3.88

市盈率(LYR):-22.40

資料載入中...

總覽公司新聞公告

概念

新冠治療股-0.37%

醫藥生物股-1.73%

ESG概念-1.22%

資金流向

資金流入：

資金流出：

新聞

英國監管機構因數據不可靠，暫停安進公司Tavneos用於新患者

CSL重大擴產計劃：大幅提升免疫球蛋白及白蛋白生產能力，惠及罕見病與重症患者

CSL達成協議：為美國藥品定價及特定232條款關税風險增添確定性

CSL有限公司：項目預計創造至少300個製藥製造業新崗位及約800個建築及相關崗位

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/CSL.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":167.1,"timestamp":1789107120000,"preClose":169.5,"halted":0,"volume":806570,"delay":0,"changeRate":-0.014159292035398263,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.459564974902398,"marketStatus":"休市中","change":-2.4,"latestTime":"09-11 16:12:00 AEST","open":167,"high":169.36,"low":165.79,"amount":134554029,"amplitude":0.021062,"askPrice":167.17,"askSize":148,"bidPrice":166.8,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-7.459564974902398,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":169.5,"dividendRate":0.024385,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":0.7945711806017333,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":169.5,"auctionPrice":167.07,"auctionVolume":285295,"auction":3,"marketStatus":"盘后竞价","timestamp":1789107002475}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.459565,"volumeRatio":0.7945711806017333,"shares":478911979,"dividePrice":4.071389,"high":169.36,"amplitude":0.021062,"preClose":169.5,"low":165.79,"week52Low":88.837,"pbRate":"3.88","psRate":"3.63","week52High":216.751,"institutionHeld":0,"latestPrice":167.1,"committee":-0.922078,"eps":-7.459564974902398,"divideRate":0.024365,"volume":806570,"delay":0,"ttmEps":-7.459564974902398,"open":167,"prevYearClose":168.21,"prevWeekClose":172.243,"prevMonthClose":169.351,"prevQuarterClose":113.256,"fiveDayClose":172.243,"twentyDayClose":134.734,"sixtyDayClose":114.815,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.01866467227077263},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664347855","title":"英國監管機構因數據不可靠，暫停安進公司Tavneos用於新患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2664347855","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664347855?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:15","pubTimestamp":1788261324,"startTime":"0","endTime":"0","summary":"英国监管机构因数据不可靠，暂停安进公司Tavneos用于新患者路透9月1日-英国药品监管机构周二暂停了安进公司旗下AMGN.O研发的罕见病药物Tavneos对新患者的使用和销售，称支持该药获批的主要研究结果不可靠。监管机构表示，由于主要临床试验的数据不可靠，该研究已无法证明该药有效，也无法证明其益处大于风险。Tavneos由ChemoCentryx公司研发，安进公司于2022年以37亿美元收购了该公司。欧洲委员会于8月撤销了Tavneos的批准，此前监管机构发现其关键试验数据不可靠。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4T44T10B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","BIB","CSL.AU","LU2468319806.SGD","AMGN","BK4588","IBBQ","LU0320765992.SGD","LU2112291526.USD","LU1061106388.HKD","LU2242652126.USD","BK4585","IE0002141913.USD","BK7511","BK4139","BK7501","LU2242646821.SGD","PJP","BK4566","IE0009355771.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU0109394709.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU2089984988.USD","BK4599","LU0122379950.USD","IBB","LU0868494617.USD","LU0889565916.HKD","LU1023059063.AUD","LU1057294990.SGD","LU1571399168.USD","BK4533","BK7067","LU1983299246.USD","BK4534","BK7508","IE00B4R5TH58.HKD","TBXU","BK4581","PBE","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160995524","title":"CSL重大擴產計劃：大幅提升免疫球蛋白及白蛋白生產能力，惠及罕見病與重症患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1160995524","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160995524?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:27","pubTimestamp":1788204431,"startTime":"0","endTime":"0","summary":"CSL宣布了一项重大扩建项目，此举将显著增强其为罕见疾病及严重病症患者生产免疫球蛋白和白蛋白的能力。这一战略性举措不仅标志着公司在生物制药领域迈出的坚实一步，更意味着全球更多患者有望获得这些关键性治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","CSL.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181327820","title":"CSL達成協議：為美國藥品定價及特定232條款關税風險增添確定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1181327820","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181327820?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:25","pubTimestamp":1788204309,"startTime":"0","endTime":"0","summary":"CSL宣布，已通过相关协议为其在美国药品定价及部分第232条款关税方面的潜在风险敞口提供了更多确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","CSL.AU","BK7511","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194972911","title":"CSL有限公司：項目預計創造至少300個製藥製造業新崗位及約800個建築及相關崗位","url":"https://stock-news.laohu8.com/highlight/detail?id=1194972911","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194972911?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:24","pubTimestamp":1788204248,"startTime":"0","endTime":"0","summary":"CSL有限公司宣布，其新项目将带来显著的就业增长。据估计，该项目将直接催生至少300个制药制造领域的全新工作岗位。与此同时，建筑业及相关配套行业也将迎来约800个就业机会。这一系列的岗位创造计划，无疑将为当地经济注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7067","BK7501","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CSL.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"新冠治療股","id":"package_au_concept_xgzlg","bkCode":"BK7501","changeRate":-0.00375},{"market":"AU","name":"醫藥生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":-0.017262},{"market":"AU","name":"ESG概念","id":"package_au_concept_esggn","bkCode":"BK7511","changeRate":-0.012242}]}}